Skip to main
MET
MET logo

MetLife (MET) Stock Forecast & Price Target

MetLife (MET) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 35%
Buy 46%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

MetLife has demonstrated resilience in its financial performance with a diverse business model, benefiting from scale and a wide array of products across its five segments, which collectively contribute to its earnings stability. The anticipated recovery in variable investment income (VII) from 25% of normal in 2023 to 75% in 2024 is projected to generate an additional $300-$325 million, bolstering the company's earnings further. Additionally, the expansion in voluntary benefits within the Group Benefits segment and the improvement in retirement spreads highlight MetLife's strong positioning in the insurance market and potential for continued growth.

Bears say

The analysis presents a negative outlook for MetLife's stock primarily due to anticipated downward adjustments in earnings per share (EPS), which are projected to be 3.5% below consensus estimates for 2024. The company is facing an estimated headwind of $300-325 million to Retirement and Income Solutions (RIS) earnings as interest rate caps roll off, along with expected base spread compression leading to further EPS declines of around $0.20 per share. Additionally, the reduction in price targets reflects a shift in the earnings multiple, indicating a cautious stance influenced by the expected challenges in key segments, particularly Group Benefits and overall RIS profitability.

MetLife (MET) has been analyzed by 26 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 46% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MetLife and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MetLife (MET) Forecast

Analysts have given MetLife (MET) a Buy based on their latest research and market trends.

According to 26 analysts, MetLife (MET) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MetLife (MET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.